皇家华人

header-logo
GettyImages-609179959-hero
headshot

Nirav N. Shah, MD

Associate Professor

view physician profile

Locations

  • Froedtert Hospital
  • Cancer Center - Froedtert Hospital

Specialties

  • Hematology
  • Medical Oncology

Languages

  • English, Gujarati

Cancer Center - Froedtert Hospital

Education

  • MD - Doctor of Medicine

Biography

Nirav Shah, MD, MSHP, is Assistant Professor of Medicine at the 皇家华人, Division of Hematology and Oncology, specializing in lymphoma, CAR-T cell therapy, and stem cell transplant at Froedtert Hospital. He graduated with honors and Alpha Omega Alpha Honor Society membership from the University of Illinois at Chicago College of Medicine in 2008. He then completed his Internal Medicine residency at Massachusetts General Hospital in Boston, Massachusetts in 2011. Post-residency, he took a position at Northwestern Memorial Hospital in Hospitalist medicine before proceeding to the University of Pennsylvania where he completed both hematology/oncology fellowship and a Master’s degree in Health Policy research in 2015.

Research Interests

Dr. Shah's current clinical and research interests include developing new cell based and immune therapies for patients with non-Hodgkin and Hodgkin lymphoma. He is specifically involved in the development of new CAR-T cell therapies for blood cancers. His professional memberships include the American Society of Hematology and the American Society of Clinical Oncology.

Dr. Shah is board certified by the American Board of Internal Medicine (ABIM) in Hematology, Medical Oncology, and Internal Medicine.

Publications

  • (Urbano-Ispizua Á, Shah NN, Kekre N.) Blood Adv. 2024 Dec 10;8(23):6133-6136 PMID: 39265170 09/12/2024

  • (Kearl TJ, Furqan F, Shah NN.) Cancer Metastasis Rev. 2024 Dec 01;44(1):12 PMID: 39617795 SCOPUS ID: 2-s2.0-85211169496 12/02/2024

  • (Akhtar OS, Arshad S, Lian Q, Ahn KW, D'Souza A, Dhakal B, Mohan M, Pasquini M, Longo W, Shah NN, Fenske TS, Hamadani M.) Transplant Cell Ther. 2024 Dec;30(12):1191.e1-1191.e8 PMID: 39303985 SCOPUS ID: 2-s2.0-85206435293 09/21/2024

  • (Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, Ujjani CS, Eyre TA, Zinzani PL, Alencar AJ, Ghia P, Lamanna N, Hoffmann MS, Patel MR, Flinn I, Gerson JN, Ma S, Coombs CC, Cheah CY, Lech-Maranda E, Fakhri B, Kim WS, Barve MA, Cohen JB, Jurczak W, Munir T, Thompson MC, Tsai DE, Bao K, Cangemi NA, Kherani JF, Walgren RA, Han H, Ruppert AS, Brown JR.) Haematologica. 2024 Oct 03 PMID: 39363864 10/04/2024

  • (Roeker LE, Woyach JA, Cheah CY, Coombs CC, Shah NN, Wierda WG, Patel MR, Lamanna N, Tsai DE, Nair B, Wang C, Zhao X, Liu D, Radtke D, Chapman S, Marella N, McNeely SC, Brown JR.) Blood. 2024 Sep 26;144(13):1374-1386 PMID: 38861666 PMCID: PMC11451378 SCOPUS ID: 2-s2.0-85198077615 06/11/2024

  • (Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel MR, Seymour JF, Woyach JA, Thompson PA, Abada PB, Ho C, McNeely SC, Marella N, Nguyen B, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Roeker LE, Ghia P.) Lancet Haematol. 2024 Sep;11(9):e682-e692 PMID: 39033770 SCOPUS ID: 2-s2.0-85200244218 07/22/2024

  • (Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M.) Blood Adv. 2024 Aug 27;8(16):4320-4329 PMID: 38889435 PMCID: PMC11372811 SCOPUS ID: 2-s2.0-85203009004 06/18/2024

  • (Peloquin S, Cymbalista F, Dreyling M, Shah NN, Murray S, Del Fiacco R, Muehlenbein CE, Lazure P.) BMC Cancer. 2024 Aug 13;24(1):1003 PMID: 39138575 PMCID: PMC11321192 SCOPUS ID: 2-s2.0-85201250614 08/14/2024

  • (Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, Ahmed N, Hill B, Hossain NM, Riedell P, Gopal AK, Grover N, Frigault M, Brammer J, Ghosh N, Merryman R, Lazaryan A, Ram R, Hertzberg M, Savani B, Awan F, Khimani F, Ahmed S, Kenkre VP, Ulrickson M, Shah N, Kharfan-Dabaja MA, Herrera A, Sauter C, Hamadani M.) Blood Cancer J. 2024 Jul 08;14(1):108 PMID: 38977682 PMCID: PMC11231252 SCOPUS ID: 2-s2.0-85197736867 07/09/2024

  • (Roeker LE, Coombs CC, Shah NN, Jurczak W, Woyach JA, Cheah CY, Patel K, Maddocks K, Wang Y, Zinzani PL, Munir T, Koh Y, Thompson MC, Muehlenbein CE, Wang C, Sizelove R, Abhyankar S, Hasanabba S, Tsai DE, Eyre TA, Wang M.) Acta Haematol. 2024 Jun 05:1-17 PMID: 38824917 PMCID: PMC11617602 06/03/2024

  • (Watt KD, Rolak S, Foley DP, Plichta JK, Pruthi S, Farr D, Zwald FO, Carvajal RD, Dudek AZ, Sanger CB, Rocco R, Chang GJ, Dizon DS, Langstraat CL, Teoh D, Agarwal PK, Al-Qaoud T, Eggener S, Kennedy CC, D'Cunha J, Mohindra NA, Stewart S, Habermann TH, Schuster S, Lunning M, Shah NN, Gertz MA, Mehta J, Suvannasankha A, Verna E, Farr M, Blosser CD, Hammel L, Al-Adra DP.) Transplantation. 2024 May 21 PMID: 38771067 SCOPUS ID: 2-s2.0-85207752060 05/21/2024

  • (Furqan F, Shah NN.) Clin Adv Hematol Oncol. 2024 Apr;22(3):140-147 PMID: 38588273 SCOPUS ID: 2-s2.0-85190320304 04/08/2024

Publications of from the

© 2024 皇家华人.  All rights reserved.  | Terms and Privacy 

Non-Discrimination Statement
The 皇家华人 (MCW) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the MCW community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. MCW’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.